Publications by authors named "Rosalba Cucci"
Article Synopsis
- In the past decade, targeted kidney inhibitors (TKIs) have significantly improved the survival rates of chronic myeloid leukemia (CML) patients, particularly those achieving deep and sustained molecular response (DMR), allowing some to consider stopping treatment.
- A study analyzed responses from 1,777 CML patients in Italy, focusing on the impact of different TKIs (imatinib, dasatinib, nilotinib) and timing of responses (3, 6, and 12 months).
- Results showed that patients achieving certain molecular response benchmarks at 3 months were more likely to achieve DMR later, with significant differences in outcomes based on the specific TKI used.
Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study.
Antonio Cuneo
,
Anthony R Mato
,
Gian Matteo Rigolin
,
Alfonso Piciocchi
,
Massimo Gentile
,
Rosalba Cucci
Cancer Med
November 2020
Article Synopsis
- Limited information exists on the effectiveness of bendamustine and rituximab (BR) in treating chronic lymphocytic leukemia (CLL) in patients with renal issues or other health conditions, leading to a study comparing this treatment to ibrutinib in real-world scenarios.
- A study involved 157 patients with lower kidney function or multiple health problems, finding that while BR was effective, those with TP53 gene disruption had shorter progression-free survival (PFS) and increased risk of death.
- The analysis revealed that ibrutinib had better PFS outcomes for advanced-stage patients compared to BR, suggesting that while BR works for some, ibrutinib may offer better long-term control for more severe cases.